Telomir Pharmaceuticals earnings were -$9.2M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest TELO earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$990.9k, down 51.9% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, TELO reported annual earnings of -$10.4M, with -37% growth.
Telomir Pharmaceuticals Earnings Reports & History FAQ
What were Telomir Pharmaceuticals's earnings last quarter?
On TELO's earnings call on Invalid Date, Telomir Pharmaceuticals (NASDAQ: TELO) reported Q1 2026 earnings per share (EPS) of -$0.03, up 57.14% year over year. Total TELO earnings for the quarter were -$990.95 thousand. In the same quarter last year, Telomir Pharmaceuticals's earnings per share (EPS) was -$0.07.
Is Telomir Pharmaceuticals profitable or losing money?
As of the last Telomir Pharmaceuticals earnings report, Telomir Pharmaceuticals is currently losing money. Telomir Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$9.22 million, a 26.31% decrease year over year.
What was TELO's earnings growth in the past year?
As of Telomir Pharmaceuticals's earnings date in Invalid Date, Telomir Pharmaceuticals's earnings has grown year over year. TELO earnings in the past year totalled -$9.22 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.